FDA Official Points To Progress On Generic Backlog; Senator Urges Action

A deputy director in FDA's drug center assured stakeholders that the agency has moved beyond the hiring and training of qualified reviewers and expects to clear out backlogged generic drug reviews in the next two years. The statement came as a senator pushed the agency to be more aggressive in tackling the growing number of pending submissions in light of rising drug prices. Lawrence Yu, deputy director for the Office of Pharmaceutical Quality, pointed to the lengthy timeline for the...